| 前收市價 | 0.0500 |
| 開市 | 0.0700 |
| 買盤 | 0.0000 |
| 賣出價 | 1.0000 |
| 拍板 | 47.50 |
| 到期日 | 2024-05-17 |
| 今日波幅 | 0.0700 - 0.0700 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 194 |
ZacksIonis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
- Reuters
REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study. Shares of Biogen and Ionis were each down nearly 2% in premarket trading. This marks another setback in the search for new treatments for ALS, a rare neurodegenerative disease that affects the voluntary control of limbs and leads to breathing trouble.
InvestorPlaceThe 3 Most Undervalued Pharma Stocks to Buy in May 2024
Here’s a question for you: What determines the value of a drug? Is it the number of lives it saves or how much it costs to make? Is it the deadliness of the disease it prevents or treats? To an individual living with diabetes, insulin is priceless, when in reality, it’s incredibly cheap to produce. On the other end of the spectrum, complex chemotherapeutics for rare cancers are exceptionally expensive due their biochemistry and production scale, but are priceless to those battling cancer. To inv
